Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.

The Fab portion of a humanized antibody (Fab-12; IgG form known as rhuMAb VEGF) to vascular endothelial growth factor (VEGF) has been affinity-matured through complementarity-determining region (CDR) mutation, followed by affinity selection using monovalent phage display. After stringent binding selections at 37 degrees C, with dissociation (off-rate) selection periods of several days, high affinity variants were isolated from CDR-H1, H2, and H3 libraries. Mutations were combined to obtain cumulatively tighter-binding variants. The final variant identified here, Y0317, contained six mutations from the parental antibody. In vitro cell-based assays show that four mutations yielded an improvement of about 100-fold in potency for inhibition of VEGF-dependent cell proliferation by this variant, consistent with the equilibrium binding constant determined from kinetics experiments at 37 degrees C. Using X-ray crystallography, we determined a high-resolution structure of the complex between VEGF and the affinity-matured Fab fragment. The overall features of the binding interface seen previously with wild-type are preserved, and many contact residues are maintained in precise alignment in the superimposed structures. However, locally, we see evidence for improved contacts between antibody and antigen, and two mutations result in increased van der Waals contact and improved hydrogen bonding. Site-directed mutants confirm that the most favorable improvements as judged by examination of the complex structure, in fact, have the greatest impact on free energy of binding. In general, the final antibody has improved affinity for several VEGF variants as compared with the parental antibody; however, some contact residues on VEGF differ in their contribution to the energetics of Fab binding. The results show that small changes even in a large protein-protein binding interface can have significant effects on the energetics of interaction.

[1]  L. Presta,et al.  Antibody Humanization Using Monovalent Phage Display* , 1997, The Journal of Biological Chemistry.

[2]  D R Burton,et al.  CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. , 1995, Journal of molecular biology.

[3]  D. Marmé,et al.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease , 1999, Cancer.

[4]  J S Tung,et al.  Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. , 1996, Journal of molecular biology.

[5]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[6]  N. Ferrara.  Vascular endothelial growth factor: molecular and biological aspects. , 1999, Current topics in microbiology and immunology.

[7]  A. Griffiths,et al.  Strategies for selection of antibodies by phage display. , 1998, Current opinion in biotechnology.

[8]  H. Lowman,et al.  Affinity maturation of human growth hormone by monovalent phage display. , 1993, Journal of molecular biology.

[9]  C. DeLisi.  Role of diffusion regulation in receptor--ligand interactions. , 1983, Methods in enzymology.

[10]  N. Ferrara,et al.  Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to Humans , 1999, Toxicologic pathology.

[11]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[12]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[13]  M Ohlin,et al.  Real Time Analysis of Antibody‐Antigen Reaction Kinetics , 1992, Scandinavian journal of immunology.

[14]  R. Karlsson,et al.  Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. , 1991, Journal of immunological methods.

[15]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[16]  A. D. de Vos,et al.  VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. , 1998, Structure.

[17]  A Tramontano,et al.  Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. , 1990, Journal of molecular biology.

[18]  Harold E. Dvorak,et al.  Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors , 1997, Thrombosis and Haemostasis.

[19]  Phage display of peptide libraries on protein scaffolds. , 1998, Methods in molecular biology.

[20]  S. Soker,et al.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. , 1992, The Journal of biological chemistry.

[21]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[22]  J. Wells,et al.  Hormone phage: An enrichment method for variant proteins with altered binding properties , 1990, Proteins.

[23]  Andrew D. Griffiths,et al.  By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling , 1992, Bio/Technology.

[24]  M. Hensler,et al.  Stepwise in vitro affinity maturation of Vitaxin, an αvβ3-specific humanized mAb , 1998 .

[25]  S. Bass,et al.  Selecting high-affinity binding proteins by monovalent phage display. , 1991, Biochemistry.

[26]  G. Winter,et al.  Antibody framework residues affecting the conformation of the hypervariable loops. , 1992, Journal of molecular biology.

[27]  G. Adams,et al.  Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. , 1996, Journal of molecular biology.

[28]  M. Hensler,et al.  Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[30]  A G Cochran,et al.  Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. , 1998, Biochemistry.

[31]  M. Karplus,et al.  Crystallographic R Factor Refinement by Molecular Dynamics , 1987, Science.

[32]  H R Hoogenboom,et al.  By-passing immunization. Human antibodies from V-gene libraries displayed on phage. , 1991, Journal of molecular biology.

[33]  B. Kay,et al.  CHAPTER 2 – Principles and Applications of Phage Display , 1996 .

[34]  T. Kunkel,et al.  Efficient site-directed mutagenesis using uracil-containing DNA. , 1991, Methods in enzymology.

[35]  G. Winter,et al.  The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. The interaction of mutant D1.3 antibodies with lysozyme. , 1993, Journal of molecular biology.

[36]  C. Scholz,et al.  A phage library-derived single-chain Fv fragment in complex with turkey egg-white lysozyme: characterization, crystallization and preliminary X-ray analysis. , 1998, Molecular immunology.

[37]  D R Burton,et al.  In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Xiang,et al.  Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops. , 1995, Journal of molecular biology.

[39]  A. D. de Vos,et al.  Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[41]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[42]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[43]  B. Keyt,et al.  The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. , 1997, Structure.

[44]  R. Nezlin.  The Immunoglobulins: Structure and Function , 1998 .

[45]  J. Wells,et al.  Additivity of mutational effects in proteins. , 1990, Biochemistry.

[46]  C. Barbas,et al.  Phage display of combinatorial antibody libraries. , 1997, Current opinion in biotechnology.

[47]  G. Winter,et al.  Selection of phage antibodies by binding affinity. Mimicking affinity maturation. , 1992, Journal of molecular biology.

[48]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[49]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .